Huayuan Securities: Maintains "buy" rating on Hutchison Medicine (00013.HK) and pays attention to the value of the ATTC platform.

According to the Wisdom Financial APP, Huayuan Securities released a research report stating that Wuhan Pharmaceuticals (00013.HK) has ample potential in its innovative pipeline, with promising prospects for the future, and maintaining a "buy" rating on the company. The bank estimates the company's total revenue for 2025-2027 to be 567, 676, and 816 million US dollars. Through DCF calculation, assuming a perpetual growth rate of 2% and a WACC of 9.43%, the company's fair equity value is 26.9 billion Hong Kong dollars (exchange rate of 1 US dollar = 7.77 Hong Kong dollars).